OR WAIT null SECS
© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
September 24, 2021
Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.
Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.
September 23, 2021
This is the fourth approval for Jakafi, a JAK1/JAK2 inhibitor.
Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.
September 22, 2021
Tivdak is the first approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer.
September 21, 2021
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 19, 2022.
September 20, 2021
The approval comes more than two months ahead of its PDUFA target date of December 4, 2021.
September 16, 2021
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.
September 14, 2021
Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.